CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Amgen - AMGN CFD

253.18
0.46%
0.99
Low: 252.47
High: 254.62
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.99
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.030779%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.013666%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Amgen Inc ESG Risk Ratings

High Medium Low Negligible

‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly

More ESG coverage

Key Stats
Prev. Close* 254.36
Open* 253.53
1-Year Change* 14.27%
Day's Range* 252.47 - 254.62
52 wk Range 214.39-296.67
Average Volume (10 days) 2.06M
Average Volume (3 months) 54.34M
Market Cap 136.00B
P/E Ratio 20.42
Shares Outstanding 533.58M
Revenue 26.33B
EPS 12.48
Dividend (Yield %) 3.34275
Beta 0.65
Next Earnings Date Feb 1, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 27, 2023 253.18 -1.00 -0.39% 254.18 254.78 252.16
Jan 26, 2023 254.36 -0.58 -0.23% 254.94 256.12 252.57
Jan 25, 2023 256.02 -3.70 -1.42% 259.72 261.13 255.52
Jan 24, 2023 259.11 -0.41 -0.16% 259.52 261.45 256.93
Jan 23, 2023 260.45 -2.68 -1.02% 263.13 264.27 259.31
Jan 20, 2023 262.82 3.73 1.44% 259.09 263.44 258.02
Jan 19, 2023 261.49 0.26 0.10% 261.23 263.11 260.31
Jan 18, 2023 263.82 -5.06 -1.88% 268.88 269.60 262.76
Jan 17, 2023 268.83 -1.89 -0.70% 270.72 273.40 268.32
Jan 13, 2023 271.36 2.20 0.82% 269.16 271.74 269.16
Jan 12, 2023 270.44 0.00 0.00% 270.44 271.57 268.00
Jan 11, 2023 272.26 -2.85 -1.04% 275.11 275.97 269.55
Jan 10, 2023 273.41 4.07 1.51% 269.34 274.15 268.61
Jan 9, 2023 269.67 -3.70 -1.35% 273.37 274.39 268.16
Jan 6, 2023 274.64 7.41 2.77% 267.23 276.36 267.23
Jan 5, 2023 266.37 3.77 1.44% 262.60 267.59 261.16
Jan 4, 2023 264.03 1.92 0.73% 262.11 264.60 260.54
Jan 3, 2023 261.04 3.44 1.34% 257.60 262.13 256.83
Dec 30, 2022 262.13 1.20 0.46% 260.93 262.67 258.89
Dec 29, 2022 262.64 -0.14 -0.05% 262.78 264.46 259.79

Amgen Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 22991 22849 23747 23362 25424 25979
Revenue 22991 22849 23747 23362 25424 25979
Cost of Revenue, Total 4162 4069 4101 4356 6159 6454
Gross Profit 18829 18780 19646 19006 19265 19525
Total Operating Expense 13197 12876 13404 13688 16285 18340
Selling/General/Admin. Expenses, Total 5062 4870 5332 5150 5730 6873
Research & Development 3840 3562 3737 4116 4207 4819
Unusual Expense (Income) -6 367 292 47
Other Operating Expenses, Total 139 8 -58 19 189 194
Operating Income 9794 9973 10343 9674 9139 7639
Interest Income (Expense), Net Non-Operating -631 -376 -798 -536 -1006 -1197
Net Income Before Taxes 9163 9597 9545 9138 8133 6701
Net Income After Taxes 7722 8079 8394 7842 7264 5893
Net Income Before Extra. Items 7722 8079 8394 7842 7264 5893
Net Income 7722 1979 8394 7842 7264 5893
Income Available to Common Excl. Extra. Items 7722 8079 8394 7842 7264 5893
Income Available to Common Incl. Extra. Items 7722 1979 8394 7842 7264 5893
Diluted Net Income 7722 1979 8394 7842 7264 5893
Diluted Weighted Average Shares 754 735 665 609 590 573
Diluted EPS Excluding Extraordinary Items 10.2414 10.9918 12.6226 12.8769 12.3119 10.2845
Dividends per Share - Common Stock Primary Issue 4 4.6 5.28 5.8 6.4 7.04
Diluted Normalized EPS 10.2347 11.4122 13.0087 12.9431 12.3119 10.2845
Total Extraordinary Items -6100
Other, Net 259
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 5901 6526 6706 6846 6238
Revenue 5901 6526 6706 6846 6238
Cost of Revenue, Total 1490 1637 1609 1718 1561
Gross Profit 4411 4889 5097 5128 4677
Total Operating Expense 3772 5698 4328 4542 3738
Selling/General/Admin. Expenses, Total 1254 2889 1305 1425 1228
Research & Development 967 1082 1422 1348 959
Other Operating Expenses, Total 61 90 -8 51 -10
Operating Income 2129 828 2378 2304 2500
Interest Income (Expense), Net Non-Operating -285 -281 -296 -335 -295
Other, Net 13 11 73 162 -530
Net Income Before Taxes 1857 558 2155 2131 1675
Net Income After Taxes 1646 464 1884 1899 1476
Net Income Before Extra. Items 1646 464 1884 1899 1476
Net Income 1646 464 1884 1899 1476
Income Available to Common Excl. Extra. Items 1646 464 1884 1899 1476
Income Available to Common Incl. Extra. Items 1646 464 1884 1899 1476
Diluted Net Income 1646 464 1884 1899 1476
Diluted Weighted Average Shares 581 576 570 564 551
Diluted EPS Excluding Extraordinary Items 2.83305 0.80556 3.30526 3.36702 2.67877
Dividends per Share - Common Stock Primary Issue 1.76 1.76 1.76 1.76 1.94
Diluted Normalized EPS 2.83305 0.80556 3.30526 3.36702 2.67877
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 46010 49476 37618 18440 21144 19385
Cash and Short Term Investments 38085 41678 29304 8911 10647 8037
Cash & Equivalents 3241 3800 6945 6037 6266 7989
Short Term Investments 34844 37878 22359 2874 4381 48
Total Receivables, Net 3165 3237 3580 4057 5324 5839
Accounts Receivable - Trade, Net 3165 3237 3580 4057 4525 4895
Total Inventory 2745 2834 2940 3584 3893 4086
Other Current Assets, Total 2015 1727 1794 1888 124 200
Total Assets 77626 79954 66416 59707 62948 61165
Property/Plant/Equipment, Total - Net 4961 4989 4958 5397 5297 5750
Property/Plant/Equipment, Total - Gross 12427 12579 12754 13754 14274 14548
Accumulated Depreciation, Total -7466 -7590 -7796 -8357 -8977 -8798
Goodwill, Net 14751 14761 14699 14703 14689 14890
Intangibles, Net 10279 8609 7443 19413 16587 15182
Long Term Investments 501 570 1176 573
Other Long Term Assets, Total 1124 1549 1698 1754 4055 5385
Total Current Liabilities 11204 9020 13488 12835 11653 12184
Accounts Payable 917 1352 1207 1371 1421 1366
Accrued Expenses 4964 5563 6948 7565 8295 8947
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 4403 1152 4419 2953 91 87
Other Current Liabilities, Total 920 953 914 946 1846 1784
Total Liabilities 47751 54713 53916 50034 53539 54465
Total Long Term Debt 30193 34190 29510 26950 32895 33222
Long Term Debt 30193 34190 29510 26950 32895 33222
Deferred Income Tax 2436 1166 864 606
Other Liabilities, Total 3918 10337 10054 9643 8991 9059
Total Equity 29875 25241 12500 9673 9409 6700
Common Stock 30784 30992 31246 31531 31802 32096
Retained Earnings (Accumulated Deficit) -438 -5072 -17977 -21330 -21408 -24600
Unrealized Gain (Loss) -138 -144 -338 22 1
Other Equity, Total -333 -535 -431 -550 -986 -796
Total Liabilities & Shareholders’ Equity 77626 79954 66416 59707 62948 61165
Total Common Shares Outstanding 738.2 722.2 629.6 591.4 578.3 558.3
Prepaid Expenses 1156 1223
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 21299 19099 24380 19385 18520
Cash and Short Term Investments 10566 8082 12921 8037 6544
Cash & Equivalents 6112 6630 11969 7989 6528
Short Term Investments 4454 1452 952 48 16
Total Receivables, Net 4423 4479 4765 4895 5077
Accounts Receivable - Trade, Net 4423 4479 4765 4895 5077
Total Inventory 4017 4115 4152 4086 4411
Other Current Assets, Total 2293 2423 2542 2367 2488
Total Assets 62539 59773 64993 61165 59196
Property/Plant/Equipment, Total - Net 4855 4906 4982 5184 5142
Goodwill, Net 14673 14676 14665 14890 14897
Intangibles, Net 15947 15308 14659 15182 14567
Other Long Term Assets, Total 5765 5784 6307 6524 6070
Total Current Liabilities 12869 14585 14842 12184 12886
Accounts Payable 1396 1277 1171 1366 1403
Accrued Expenses 9917 8984 9383 10731 10639
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1556 4324 4288 87 844
Total Liabilities 53205 51526 56776 54465 58280
Total Long Term Debt 31129 28458 33291 33222 36010
Long Term Debt 31129 28458 33291 33222 36010
Other Liabilities, Total 9207 8483 8643 9059 9384
Total Equity 9334 8247 8217 6700 916
Common Stock 31806 31877 31989 32096 31247
Retained Earnings (Accumulated Deficit) -21639 -22762 -22964 -24600 -29568
Unrealized Gain (Loss) 1 1 0 0
Other Equity, Total -834 -869 -808 -796 -763
Total Liabilities & Shareholders’ Equity 62539 59773 64993 61165 59196
Total Common Shares Outstanding 575.3 569.6 565 558.3 534.2
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line 7722 1979 8394 7842 7264 5893
Cash From Operating Activities 10354 11177 11296 9150 10497 9261
Cash From Operating Activities 2105 1955 1946 2206 3601 3398
Deferred Taxes 183 -1330 -363 -289 -287 -453
Non-Cash Items 343 663 697 122 135 1617
Cash Taxes Paid 1100 1500 1900 1900 1400 1900
Cash Interest Paid 1300 1300 1500 1300 1200 1200
Changes in Working Capital 1 7910 622 -731 -216 -1194
Cash From Investing Activities -8658 -4024 14339 5709 -5401 733
Capital Expenditures -837 -664 -738 -618 -608 -880
Other Investing Cash Flow Items, Total -7821 -3360 15077 6327 -4793 1613
Cash From Financing Activities -2599 -6594 -22490 -15767 -4867 -8271
Financing Cash Flow Items -284 -140 -68 -42 -90 -78
Total Cash Dividends Paid -2998 -3365 -3507 -3509 -3755 -4013
Issuance (Retirement) of Stock, Net -2910 -3160 -17794 -7702 -3486 -4975
Issuance (Retirement) of Debt, Net 3593 71 -1121 -4514 2464 795
Net Change in Cash -903 559 3145 -908 229 1723
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 1646 2110 3994 5893 1476
Cash From Operating Activities 2104 4035 6453 9261 2164
Cash From Operating Activities 841 1696 2546 3398 841
Deferred Taxes -91 -137 -264 -453 -251
Non-Cash Items 79 1675 1692 1617 545
Changes in Working Capital -371 -1309 -1515 -1194 -447
Cash From Investing Activities -319 890 963 733 -111
Capital Expenditures -166 -351 -593 -880 -190
Other Investing Cash Flow Items, Total -153 1241 1556 1613 79
Cash From Financing Activities -1939 -4561 -1713 -8271 -3514
Financing Cash Flow Items -52 -85 -104 -78 -26
Total Cash Dividends Paid -1016 -2024 -3023 -4013 -1080
Issuance (Retirement) of Stock, Net -871 -2452 -3532 -4975 -6360
Issuance (Retirement) of Debt, Net 0 0 4946 795 3952
Net Change in Cash -154 364 5703 1723 -1461
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 8.849 47216165 1317764 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.4633 29151093 277320 2022-09-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 5.4487 29073061 -207866 2022-09-30 LOW
PRIMECAP Management Company Investment Advisor 2.9171 15564870 -73750 2022-09-30 LOW
Capital Research Global Investors Investment Advisor 2.3624 12605265 -1490071 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 2.0992 11200793 502787 2022-09-30 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 1.7311 9236530 287899 2022-09-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 1.5266 8145601 -212030 2022-09-30 LOW
Morgan Stanley Smith Barney LLC Investment Advisor 1.5255 8139945 -45470 2022-09-30 LOW
Invesco Capital Management (QQQ Trust) Investment Advisor 1.334 7118039 -705787 2022-12-31 LOW
Wells Fargo Advisors Research Firm 1.3251 7070379 59546 2022-09-30 LOW
Goldman Sachs & Company, Inc. Research Firm 1.2368 6599371 1971000 2022-09-30 MED
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.9488 5062588 -492241 2021-12-31 LOW
BlackRock Asset Management Ireland Limited Investment Advisor 0.9193 4905395 163471 2022-09-30 LOW
Aristotle Capital Management, LLC Investment Advisor 0.9165 4890166 -72128 2022-09-30 LOW
BofA Global Research (US) Research Firm 0.8962 4781857 -445255 2022-09-30 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.8092 4317814 -103045 2022-09-30 LOW
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.7975 4255525 -170586 2022-09-30 LOW
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.7689 4102655 -193979 2022-09-30 LOW
JP Morgan Asset Management Investment Advisor 0.7674 4094846 20049 2022-09-30 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+485000+

Traders

65000+

Active clients monthly

$48000000+

Monthly investing volume

$28000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Amgen Company profile

About Amgen, Inc.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Amgen, Inc. revenues increased 2% to $25.98B. Net income decreased 19% to $5.89B. Revenues reflect Other revenues segment increase of 42% to $1.68B, Prolia segment increase of 18% to $3.25B, ROW segment increase of 12% to $7.01B, Other revenues segment increase of 42% to $1.68B. Net income was offset by Research and development increase of 15% to $4.82B (expense), Other increase of 3% to $194M (expense).

Equity composition

Common Stock $.0001 Par, 4/11, 2.75B auth., 929,730,507 issd. Insiders own 0.12% . IPO 5/87, 2M shares @ $34 by Paine Webber. 9/91, 3-for-1 split; 11/99, 3/99, 8/95, 7/90, 2-for-1 splits. 7/02, Company acquired Immunex Corp. @ $4.50/share and 0.44 shs. (242,916,735 shs. issd.).

Industry: Pharmaceuticals (NEC)

One Amgen Center Drive
THOUSAND OAKS
CALIFORNIA 91320-1799
US

Income Statement

  • Annual
  • Quarterly

People also watch

Natural Gas

2.86 Price
+0.740% 1D Chg, %
Long position overnight fee -0.0485%
Short position overnight fee 0.0282%
Overnight fee time 22:00 (UTC)
Spread 0.005

BTC/USD

23,043.60 Price
-0.390% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

US100

12,164.80 Price
+1.340% 1D Chg, %
Long position overnight fee -0.0179%
Short position overnight fee 0.0070%
Overnight fee time 22:00 (UTC)
Spread 3.0

ETH/USD

1,595.68 Price
-0.440% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 5.00

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading